Chinese Journal of Stroke ›› 2018, Vol. 13 ›› Issue (06): 580-585.DOI: 10.3969/j.issn.1673-5765.2018.06.009
Previous Articles Next Articles
Received:
2018-04-10
Online:
2018-06-20
Published:
2018-06-20
周沐科,郭毅佳,董书菊,何俐
通讯作者:
何俐 heli2003new@126.com
ZHOU Mu-Ke, GUO Yi-Jia, DONG Shu-Ju, HE Li. The Role of Statin in Primary Prevention of Ischemic Stroke[J]. Chinese Journal of Stroke, 2018, 13(06): 580-585.
周沐科, 郭毅佳, 董书菊, 何俐. 他汀在缺血性卒中一级预防中的作用[J]. 中国卒中杂志, 2018, 13(06): 580-585.
[1] WANG W,JIANG B,SUN H,et al. Prevalence,incidence,and mortality of stroke in China:resultsfrom a nationwide population-based survey of480 687 adults[J]. Circulation,2017,135(8):759-771.[2] 中国卒中学会科学声明专家组. 急性缺血性卒中静脉溶栓:中国卒中学会科学声明[J]. 中国卒中杂志,2017,12(3):267-284.[3] DONG Q,DONG Y,LIU L,et al. The ChineseStroke Association scientific statement:intravenousthrombolysis in acute ischaemic stroke[J]. StrokeVasc Neurol,2017,2(3):147-159.[4] KIM J T,FONAROW G C,SMITH E E,et al.Treatment With Tissue Plasminogen Activator in theGolden Hour and the Shape of the 4. 5-Hour Time-Benefit Curve in the National United States Get WithThe Guidelines-Stroke Population[J]. Circulation,2017,135(2):128-139.[5] SEVER P S,DAHLÖF B,POULTER N R,etal. Prevention of coronary and stroke eventswith atorvastatin in hypertensive patients whohave average or lower-than-average cholesterolconcentrations,in the Anglo-Scandinavian CardiacOutcomes Trial--Lipid Lowering Arm(ASCOTLLA):a multicentre randomised controlled trial[J].Lancet,2003,361(9364):1149-1158.[6] HASSAN Y,AL-JABI S W,AZIZ N A,et al. Effectof prestroke use of angiotensin-converting enzymeinhibitors alone versus combination with antiplateletsand statin on ischemic stroke outcome[J]. ClinNeuropharmacol,2011,34(6):234-240.[7] HITMAN G A,COLHOUN H,NEWMAN C,etal. Stroke prediction and stroke prevention withatorvastatin in the Collaborative AtorvastatinDiabetes Study(CARDS)[J]. Diabet Med,2007,24(12):1313-1321.[8] COLHOUN H M,BETTERIDGE D J,DURRINGTON P N,et al. Primary prevention ofcardiovascular disease with atorvastatin in type 2diabetes in the Collaborative Atorvastatin DiabetesStudy(CARDS):multicentre randomised placebocontrolledtrial[J]. Lancet,2004,364(9435):685-696.[9] COLLINS R,ARMITAGE J,PARISH S,et al.MRC/BHF Heart Protection Study of cholesterolloweringwith simvastatin in 5963 people withdiabetes:a randomised placebo-controlled trial[J].Lancet,2003,361(9374):2005-2016.[10] NAKAYA N,MIZUNO K,OHASHI Y,et al.Low-dose pravastatin and age-related differencesin risk factors for cardiovascular disease inhypercholesterolaemic Japanese:analysis of themanagement of elevated cholesterol in the primaryprevention group of adult Japanese(MEGA study)[J]. Drugs Aging,2011,28(9):681-692.[11] MATSUSHIMA T,NAKAYA N,MIZUNO K,etal. The effect of low-dose pravastatin in metabolicsyndrome for primary prevention of cardiovasculardisease in Japan:a post hoc analysis of the MEGAstudy[J]. J Cardiovasc Pharmacol Ther,2012,17(2):153-158.[12] WATERS D D,LAROSA J C,BARTER P,et al.Effects of high-dose atorvastatin on cerebrovascularevents in patients with stable coronary disease in theTNT(treating to new targets)study[J]. J Am CollCardiol,2006,48(9):1793-1799.[13] MILLS E J,O'REGAN C,EYAWO O,et al.Intensive statin therapy compared with moderatedosing for prevention of cardiovascular events:ameta-analysis of >40 000 patients[J]. Eur Heart J,2011,32(11):1409-1415.[14] ZHAO S P,YU B L,PENG D Q,et al. The effect ofmoderate-dose versus double-dose statins on patientswith acute coronary syndrome in China:Results ofthe CHILLAS trial[J]. Atherosclerosis,2014,233(2):707-712.[15] CANNON C P,BLAZING M A,GIUGLIANO R P,et al. Ezetimibe added to statin therapy after acutecoronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397.[16] EISEN A,CANNON C P,BLAZING M A,et al.The benefit of adding ezetimibe to statin therapyin patients with prior coronary artery bypassgraft surgery and acute coronary syndrome in theIMPROVE-IT trial[J]. Eur Heart J,2016,37(48):3576-3584.[17] RIDKER P M,DANIELSON E,FONSECA F A,etal. Rosuvastatin to prevent vascular events in menand women with elevated C-reactive protein[J]. NEngl J Med,2008,359(21):2195-2207.[18] RIDKER P M,MACFADYEN J G,NORDESTGAARD B G,et al. Rosuvastatinfor primary prevention among individuals withelevated high-sensitivity c-reactive protein and 5%to 10% and 10% to 20% 10-year risk. Implicationsof the Justification for Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin(JUPITER)trial for "intermediate risk"[J]. CircCardiovasc Qual Outcomes,2010,3(5):447-452.[19] TAYLOR F,HUFFMAN M D,MACEDO A F,et al.Statins for the primary prevention of cardiovasculardisease[J/OL]. Cochrane Database Syst Rev,2013,(1):CD004816. http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004816.pub5/abstract;jsessionid=531B642963A49795A5C67C417A999369.f01t02. DOI:10.1002/14651858.CD004816.pub5.[20] Cholesterol Treatment Trialists(' CTT)Collaborators,MIHAYLOVA B,EMBERSON J,et al. The effectsof lowering LDL cholesterol with statin therapy inpeople at low risk of vascular disease:meta-analysisof individual data from 27 randomised trials[J].Lancet,2012,380(9841):581-590.[21] TONELLI M,LLOYD A,CLEMENT F,et al.Efficacy of statins for primary prevention in peopleat low cardiovascular risk:a meta-analysis[J/OL].CMAJ,2011,183(16):E1189-E1202. https://doi.org/10.1503/cmaj.101280.[22] THANASSOULIS G,WILLIAMS K,ALTOBELLIK K,et al. Individualized statin benefit fordetermining statin eligibility in the primaryprevention of cardiovascular disease[J]. Circulation,2016,133(16):1574-1581.[23] HELLER D J,COXSON P G,PENKO J,et al.Evaluating the impact and cost-effectiveness of statinuse guidelines for primary prevention of coronaryheart disease and stroke[J]. Circulation,2017,136(12):1087-1098.[24] GREISENEGGER S,MÜLLNER M,TENTSCHERT S,et al. Effect of pretreatmentwith statins on the severity of acute ischemiccerebrovascular events[J]. J Neurol Sci,2004,221(1-2):5-10.[25] CHOI J C,LEE J S,PARK T H,et al. Effect ofpre-stroke statin use on stroke severity and earlyfunctional recovery:a retrospective cohort study[J/OL]. BMC Neurol,2015,15:120. https://doi.org/10.1186/s12883-015-0376-3.[26] DESMAELE S,CORNU P,BARBÉ K,et al.Relationship between pre-stroke cardiovascularmedication use and stroke severity[J]. Eur J ClinPharmacol,2016,72(4):495-502.[27] ISHIKAWA H,WAKISAKA Y,MATSUO R,etal. Influence of statin pretreatment on initialneurological severity and short-term functionaloutcome in acute ischemic stroke patients:theFukuoka Stroke Registry[J]. Cerebrovasc Dis,2016,42(5-6):395-403.[28] MARTÍ-FÀBREGAS J,GOMIS M,ARBOIX A,etal. Favorable outcome of ischemic stroke in patients pretreated with statins[J]. Stroke,2004,35(5):1117-1121.[29] ABOA-EBOULÉ C,BINQUET C,JACQUIN A,etal. Effect of previous statin therapy on severity andoutcome in ischemic stroke patients:a populationbasedstudy[J]. J Neurol,2013,260(1):30-37.[30] ASLANYAN S,WEIR C J,MCINNES G T,et al.Statin administration prior to ischaemic stroke onsetand survival:exploratory evidence from matchedtreatment-control study[J]. Eur J Neurol,2005,12(7):493-498.[31] HASSAN Y,AL-JABI S W,AZIZ N A,et al. Statinuse prior to ischemic stroke onset is associated withdecreased in-hospital mortality[J]. Fundam ClinPharmacol,2011,25(3):388-394.[32] TSIVGOULIS G,KATSANOS A H,SHARMA VK,et al. Statin pretreatment is associated with betteroutcomes in large artery atherosclerotic stroke[J].Neurology,2016,86(12):1103-1111.[33] TZIOMALOS K,GIAMPATZIS V,BOUZIANAS D,et al. Effect of prior treatment with differentstatins on stroke severity and functional outcome atdischarge in patients with acute ischemic stroke[J/OL]. Int J Stroke,2013,8(7):E49. https://doi.org/10.1111/ijs.12116.[34] REEVES M J,GARGANO J W,LUO Z,et al.Effect of pretreatment with statins on ischemicstroke outcomes[J]. Stroke,2008,39(6):1779-1785.[35] Alvarez-Sabin J,Huertas R,Quintana M,et al.Prior statin use may be associated with improvedstroke outcome after tissue plasminogen activator[J].Stroke,2007,38(3):1076-1078.[36] MARTINEZ-RAMIREZ S,DELGADOMEDEROSR,MARIN R,et al. Statin pretreatmentmay increase the risk of symptomatic intracranialhaemorrhage in thrombolysis for ischemic stroke:results from a case-control study and a metaanalysis[J]. J Neurol,2012,259(1):111-118.[37] NICHOLAS J S,SWEARINGEN C J,THOMAS JC,et al. The effect of statin pretreatment on infarctvolume in ischemic stroke[J]. Neuroepidemiology,2008,31(1):48-56.[38] OVBIAGELE B,SAVER J L,STARKMAN S,etal. Statin enhancement of collateralization in acutestroke[J]. Neurology,2007,68(24):2129-2131.[39] YI X,HAN Z,WANG C,et al. Statin and aspirinpretreatment are associated with lower neurologicaldeterioration and platelet activity in patients withacute ischemic stroke[J]. J Stroke Cerebrovasc Dis,2017,26(2):352-359.[40] TSAI N W,LIN T K,CHANG W N,et al. Statinpre-treatment is associated with lower plateletactivity and favorable outcome in patients with acutenon-cardio-embolic ischemic stroke[J/OL]. Crit Care,2011,15(4):R163. https://doi.org/10.1186/cc10303.[41] SAFOURIS A,KROGIAS C,SHARMA V K,etal. Statin pretreatment and microembolic signals inlarge artery atherosclerosis[J]. Arterioscler ThrombVasc Biol,2017,37(7):1415-1422.[42] ZHAO S,WANG Y,MU Y,et al. Prevalence ofdyslipidaemia in patients treated with lipid-loweringagents in China:results of the DYSlipidemiaInternational Study(DYSIS)[J]. Atherosclerosis,2014,235(2):463-469.[43] WANG A,YANG Y,SU Z,et al. Association ofoxidized low-density lipoprotein with prognosis ofstroke and stroke subtypes[J]. Stroke,2017,48(1):91-97.[44] YAMASHITA S,MASUDA D,OHAMA T,etal. Rationale and design of the PROSPECTIVEtrial:probucol trial for secondary prevention ofatherosclerotic events in patients with prior coronaryheart disease[J]. J Atheroscler Thromb,2016,23(6):746-756.[45] GIUGLIANO R P,WIVIOTT S D,BLAZING MA,et al. Long-term safety and efficacy of achievingvery low levels of low-density lipoprotein cholesterol:a prespecified analysis of the IMPROVE-IT trial[J].JAMA Cardiol,2017,2(5):547-555.[46] SABATINE M S,GIUGLIANO R P,KEECH A C,et al. Evolocumab and clinical outcomes in patientswith cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722. |
[1] | WANG Kaiwen, LU Baoquan, WU Xiuling, MA Jiali. A Novel BAOPS-MRA Score Predicts Outcome in Nonsevere Basilar Artery Occlusion [J]. Chinese Journal of Stroke, 2022, 17(12): 1335-1342. |
[2] | WU Yuqian, ZHANG Yumei, FAN Xiaowei, WANG Anxin, PANG Wenbin. The Efficacy of Kinesthetic Motor Imagery Therapy for Hand Function Rehabilitation of Stroke Patients [J]. Chinese Journal of Stroke, 2022, 17(12): 1366-1371. |
[3] | WU Xiaoli, LIU Lixu. The Effect of Obesity on Prognosis of Stroke [J]. Chinese Journal of Stroke, 2022, 17(12): 1391-1395. |
[4] | YI Luo, ZHOU Hongyu, QIU Xin, LI Zixiao, WANG Yongjun. DNA Methylation Changes in Atherosclerotic Diseases [J]. Chinese Journal of Stroke, 2022, 17(11): 1163-1170. |
[5] | WANG Yubo, LI Zixiao, WANG Yongjun. Progress of the Relationship between Epigenetics and Oxidative Stress after Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(11): 1171-1177. |
[6] | CUI Lingyun, QIU Xin, ZHOU Hongyu, LI Zixiao, WANG Yongjun. Progress of the Relationship between DNA Methylation and Type 2 Diabetes [J]. Chinese Journal of Stroke, 2022, 17(11): 1183-1188. |
[7] | DENG Yuhan, LIU Shuang, WANG Ziyao, WANG Yuxin, LIU Baohua. The Effect of Machine Learning Model for Predicting Stroke Risk in the General Population Based on Structured Data: A Systematic Review and Meta-Analysis [J]. Chinese Journal of Stroke, 2022, 17(11): 1189-1197. |
[8] | LIU Guangliang, HAN Kaiyue, SU Wenlong, ZHANG Hao. Effects of Aerobic Cycling Training Intensity on Motor and Cardiopulmonary Fitness in Patients with Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(11): 1203-1208. |
[9] | XU Yingxin, ZHANG Shuang, ZHOU Xiaomei, YUAN Jinglin, ZHAO Liuzhuang, YANG Haihua. Correlation of Non-Stenotic Carotid Plaque with Anterior Circulation Embolic Stroke of Undetermined Source [J]. Chinese Journal of Stroke, 2022, 17(11): 1233-1237. |
[10] | CHENG Shi, LI Jing, GUO Junping, HU Aixiang, YU Xinwei, HAN Wei, LIANG Ying, ZHANG Yuewei, JI Ruijun. Clinical Characteristics and Risk Factors of Infection in Patients with Acute Stroke during Hospitalization [J]. Chinese Journal of Stroke, 2022, 17(10): 1065-1070. |
[11] | XIANG Wei, XU Luyao, ZHANG Manman, WEI Hongchun, LIANG Zhigang. The Frequency and Influencing Factors of Asymmetrical Prominent Veins Sign on Susceptibility-Weighted Imaging in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1097-1102. |
[12] | ZHAO Yongrui, LIU Zhanhui. Progress of Diffusion Tensor Imaging in Evaluating Motor Function Prognosis of Patients with Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1114-1119. |
[13] | ZHANG Boyu, GUO Yucheng, CUI Yuxia, LI Yingli, LYU Yumei. Seeking Medical Services Decision-Making Status and Relevant Influencing Factors in Patients with Acute Ischemic Stroke: A Review [J]. Chinese Journal of Stroke, 2022, 17(10): 1127-1132. |
[14] | WU Tingting, LIU Yafei, YAN Shixi, WU Yiping, ZHANG Zhongbo, ZAHNG Hanfei, FANG Pinping. Application of “Internet Plus” in Emergency Care of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1133-1138. |
[15] | ZHANG Yige, ZHANG Wan, ZHANG Luyang, WANG Xin, DING Lan, WANG Yuying, PEI Lulu, FANG Hui, XU Yuming, SONG Bo. Association of Artery Occlusion and Recurrent Ischemic Stroke Related with Cerebral Artery Dissection [J]. Chinese Journal of Stroke, 2022, 17(09): 932-936. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||